Results 11 to 20 of about 9,774 (195)

Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex. [PDF]

Transfusion
Abstract Background Cryoprecipitate Anti‐Haemophilic Factor (CRYO‐AHF) is enriched for fibrinogen, VWF, FVIII, FXIII and fibronectin, but has short post‐thaw expiration due to risk of transfusion‐transmitted infection (TTI) limiting availability for rapid treatment.
Tupin F, Mouriaux C, Gatmaitan M, Kaastrup K, Yegneswaran S, Corash L, Mangin PH.   +6 more
europepmc   +2 more sources

Pathogen-reduced plasma, cryoprecipitate reduced for therapeutic plasma exchange. [PDF]

Transfusion
Abstract Background Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) and auto‐immune disorders involves repeated patient exposure to allogenic plasma with the risk of transfusion‐transmitted infection (TTI).
Tupin F, Mouriaux C, Hechler B, Kaastrup K, Yegneswaran S, Corash L, Mangin PH.   +6 more
europepmc   +2 more sources

Modeling Versus Balancing Approaches to Addressing Instrumental Variables in Weighting: A Comparison of the Outcome-Adaptive Lasso, Stable Balancing Weighting, and Stable Confounder Selection. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Background Variable selection is essential for propensity score (PS)‐weighted estimators. Recent work shows that including instrumental variables (IVs), associated with only treatment but not with the outcome, can impact both the bias and precision of the PS‐weighted estimators.
Choi BY, Brookhart MA.
europepmc   +2 more sources

Breaking the Barrier: Unraveling the No-Reflow Phenomenon in Cardiovascular Medicine. [PDF]

Catheter Cardiovasc Interv
ABSTRACT The no‐reflow phenomenon is a stubborn and often devastating complication in cardiovascular medicine, where blood flow is restored to an artery, yet the microvasculature remains unresponsive. First identified in 1967, this phenomenon has haunted clinicians and researchers alike, particularly in the context of acute myocardial infarction (AMI).
Howes S, Altaee O, Ramirez A, Calaquian L, Asif A, Stone C, Hammadah M, Roy D, Ramsey B, Chilton R.   +9 more
europepmc   +2 more sources

Abciximab in rescue therapy of thromboembolic events during endovascular treatment of cerebral aneurysms: single center experience of 49 cases [PDF]

Frontiers in Neurology
BackgroundThe aim of this study was to assess the safety and effectiveness of abciximab (ReoPro®), a glycoprotein-IIb/IIIa receptor antagonist, in the management of thromboembolic complications during endovascular treatment of intracranial aneurysms ...
Lukas Lenhart, Valentin Ladenhauf, Verena Rass, Stephanie A. Treichl, Ronny Beer, Christian F. Freyschlag, Elke R. Gizewski, Astrid E. Grams   +7 more
doaj   +2 more sources

Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper. [PDF]

Allergy
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Cortellini G, Nakonechna A, Barbaud A, Bavbek S, Calogiuri G, Doña I, Kvedariene V, Laguna Martinez JJ, Liberati S, Pagani M, Romano A.   +10 more
europepmc   +2 more sources

The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab [PDF]

Cardiology Journal
BACKGROUND: Our study compared the effect of P2Y12 receptor inhibitors in combination with abciximab on clinical outcomes in patients with acute coronary syndrome (ACS).
Onur Altınkaya, Selim Aydemir, Murat Özmen, Sidar Şiyar Aydın, Emrah Aksakal, Mustafa Özkoç, Rauf Macit, İbrahim Saraç, Yavuzer Koza, Muhammet Hakan Taş   +9 more
doaj   +2 more sources

Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s) [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken, Arnoud W. J. van 't Hof, Jurriën M. ten Berg, Dean J. Kereiakes, Barry S. Coller   +4 more
doaj   +2 more sources

Development of Reference Intervals for the TEG 6s, a Point-of-Care Viscoelastic Assay, in Dogs. [PDF]

Vet Clin Pathol
ABSTRACT Background Thromboelastography (TEG) provides a global assessment of hemostasis and identifies patients with both hemorrhagic and thrombotic tendencies. Traditional TEG instruments, such as the TEG 5000 (Haemonetics), can be labor‐intensive and require specialized training to operate.
Wilkinson AR, Conner BJ, Serpa PBS.
europepmc   +2 more sources

Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents [PDF]

Blood Vessels, Thrombosis & Hemostasis
: Mouse models, such as the intravital laser-induced model of thrombus formation, are commonly used for mechanistic and preclinical studies in thrombosis. However, their translational value is limited by species differences.
Alexander Dupuy, Miao Qi, Jemma C. L. Fenwick, Daisie M. Yates, Paul R. Coleman, Jennifer R. Gamble, Lining Arnold Ju, Freda H. Passam   +7 more
doaj   +2 more sources